Mode
Home
Conditions Medications Drug Pipeline Weekly Digests Questions
Text Size
Log in / Sign up
Home › Questions

Is adjuvant BCG better than Epirubicin for intermediate-risk non-muscle invasive bladder cancer patients?

moderate confidence  ·  Last reviewed May 17, 2026

For intermediate-risk non-muscle invasive bladder cancer (NMIBC), doctors often choose between intravesical BCG (a type of immunotherapy) and chemotherapy drugs like epirubicin. A 2024 study directly comparing BCG and epirubicin found no significant difference in recurrence or progression rates, though BCG was linked to a longer average time before recurrence. Other research supports that both treatments are effective options, and the choice may depend on side effects and patient preference.

What the research says

A randomized trial of 134 intermediate-risk NMIBC patients compared adjuvant intravesical BCG to epirubicin. Over a mean follow-up of 19 months, recurrence rates were 19.4% for BCG versus 28.5% for epirubicin, and progression rates were 6.5% versus 5% — differences that were not statistically significant. However, the mean time to recurrence was significantly longer with BCG (18 months) compared to epirubicin (16.7 months) 3. A larger multicenter study of 2206 intermediate-risk patients found that any adjuvant therapy (BCG or chemotherapy like epirubicin) improved recurrence-free survival compared to no treatment, but did not find a significant difference between BCG and chemotherapy specifically 6. Another trial from the FinnBladder group compared BCG to a combination of epirubicin plus interferon in intermediate-risk patients and found BCG significantly reduced the probability of recurrence (39% vs. 52% at 7.5 years) 7. Overall, the evidence suggests BCG may offer a slight advantage in preventing recurrence, but the differences are modest and both treatments are considered reasonable options.

What to ask your doctor

  • Given my specific tumor features and risk factors, would BCG or epirubicin be more appropriate for me?
  • What are the common side effects of BCG and epirubicin, and how do they compare?
  • How long would the treatment course be for each option, and what does the follow-up schedule look like?
  • Are there any newer treatments, like gemcitabine/docetaxel, that might be considered for my case?
  • If I experience side effects, are there ways to manage them or switch treatments?

This question is drawn from common patient questions about this topic and answered using cited medical research. We do not provide individualized advice.